Literature DB >> 26352110

KRAS, NRAS, BRAF mutations and high counts of poorly differentiated clusters of neoplastic cells in colorectal cancer: observational analysis of 175 cases.

Valeria Barresi1, Luca Reggiani Bonetti, Stefania Bettelli.   

Abstract

A novel grading system based on the counting of poorly differentiated clusters (PDC) of neoplastic cells at the invasive margin and in the tumour stroma was recently introduced among the histological parameters predictive of adverse clinical outcome in colorectal cancer (CRC). The aim of this study was to correlate the histological grade based on PDC and the mutational status of KRAS, NRAS and BRAF genes in 175 consecutive CRCs. The highest PDC count under the objective lens of a ×20 microscopic field in each tumour was considered for grading assessment, so that PDC counts <5, 5-9 and ≥10 PDCs were defined grade 1, grade 2 and grade 3, respectively. Hotspots mutations were identified using the MassArray platform. Overall, there were 42 (24%) mutated tumours. Mutational status was significantly associated with high pT stage (p = 0.0021), advanced pTNM stage (p = 0.0018), nodal metastases (p = 0.006), tumour budding (p = 0.022) and high PDC grade (p = 0.0022). KRAS mutations were significantly associated with PDC grade (p = 0.0379), while BRAF mutations were associated with PDC-G3 although statistical significance was not reached. No significant associations were found between NRAS and PDC. The significant association between mutated KRAS and PDC grade suggests that KRAS mutations may be involved in the formation of PDC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26352110     DOI: 10.1097/PAT.0000000000000300

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  19 in total

1.  Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern.

Authors:  Humaid O Al-Shamsi; Jeremy Jones; Yazan Fahmawi; Ibrahim Dahbour; Aziz Tabash; Reham Abdel-Wahab; Ahmed O S Abousamra; Kenna R Shaw; Lianchun Xiao; Manal M Hassan; Benjamin R Kipp; Scott Kopetz; Amr S Soliman; Robert R McWilliams; Robert A Wolff
Journal:  J Gastrointest Oncol       Date:  2016-12

Review 2.  Tumour budding in solid cancers.

Authors:  Alessandro Lugli; Inti Zlobec; Martin D Berger; Richard Kirsch; Iris D Nagtegaal
Journal:  Nat Rev Clin Oncol       Date:  2020-09-08       Impact factor: 66.675

3.  Effects of PHA-665752 and vemurafenib combination treatment on in vitro and murine xenograft growth of human colorectal cancer cells with BRAFV600E mutations.

Authors:  Jie Zhi; Zhongxin Li; Jian Lv; Bo Feng; Donghai Yang; Liang Xue; Zhaolong Zhao; Yanni Zhang; Jianhua Wu; Yingchao Jv; Yitao Jia
Journal:  Oncol Lett       Date:  2018-01-10       Impact factor: 2.967

4.  Pan-cancer image-based detection of clinically actionable genetic alterations.

Authors:  Alexander T Pearson; Tom Luedde; Jakob Nikolas Kather; Lara R Heij; Heike I Grabsch; Chiara Loeffler; Amelie Echle; Hannah Sophie Muti; Jeremias Krause; Jan M Niehues; Kai A J Sommer; Peter Bankhead; Loes F S Kooreman; Jefree J Schulte; Nicole A Cipriani; Roman D Buelow; Peter Boor; Nadi-Na Ortiz-Brüchle; Andrew M Hanby; Valerie Speirs; Sara Kochanny; Akash Patnaik; Andrew Srisuwananukorn; Hermann Brenner; Michael Hoffmeister; Piet A van den Brandt; Dirk Jäger; Christian Trautwein
Journal:  Nat Cancer       Date:  2020-07-27

5.  KRAS, NRAS, and BRAF mutation prevalence, clinicopathological association, and their application in a predictive model in Mexican patients with metastatic colorectal cancer: A retrospective cohort study.

Authors:  Hector Eduardo Sanchez-Ibarra; Xianli Jiang; Elena Yareli Gallegos-Gonzalez; Adriana Carolina Cavazos-González; Yenho Chen; Faruck Morcos; Hugo Alberto Barrera-Saldaña
Journal:  PLoS One       Date:  2020-07-06       Impact factor: 3.240

6.  A Case of Colonic Micropapillary Carcinoma with a High Frequency of Apoptosis.

Authors:  Kazumori Arai; Tomohiro Iwasaki; Hisato Ishimatsu; Chinatsu Tsuchiya; Aki Kubota; Akihiro Sonoda; Ko Ohata
Journal:  J Gastrointest Cancer       Date:  2021-07-24

Review 7.  Poorly differentiated clusters (PDC) in colorectal cancer: what is and ought to be known.

Authors:  Luca Reggiani Bonetti; Valeria Barresi; Stefania Bettelli; Federica Domati; Cristian Palmiere
Journal:  Diagn Pathol       Date:  2016-03-22       Impact factor: 2.644

8.  Tumour budding, poorly differentiated clusters, and T-cell response in colorectal cancer.

Authors:  Kenji Fujiyoshi; Juha P Väyrynen; Jennifer Borowsky; David J Papke; Kota Arima; Koichiro Haruki; Junko Kishikawa; Naohiko Akimoto; Tomotaka Ugai; Mai Chan Lau; Simeng Gu; Shanshan Shi; Melissa Zhao; Annacarolina Fabiana Lucia Da Silva; Tyler S Twombly; Hongmei Nan; Jeffrey A Meyerhardt; Mingyang Song; Xuehong Zhang; Kana Wu; Andrew T Chan; Charles S Fuchs; Jochen K Lennerz; Marios Giannakis; Jonathan A Nowak; Shuji Ogino
Journal:  EBioMedicine       Date:  2020-07-08       Impact factor: 8.143

9.  Active K-RAS induces the coherent rotation of epithelial cells: A model for collective cell invasion in vitro.

Authors:  Eishu Hirata; Takehiko Ichikawa; Shin-Ichi Horike; Etsuko Kiyokawa
Journal:  Cancer Sci       Date:  2018-11-05       Impact factor: 6.716

10.  Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data.

Authors:  Anne Trinh; Claudia Lädrach; Heather E Dawson; Sanne Ten Hoorn; Peter J K Kuppen; Marlies S Reimers; Miriam Koopman; Cornelis J A Punt; Alessandro Lugli; Louis Vermeulen; Inti Zlobec
Journal:  Br J Cancer       Date:  2018-11-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.